NCT02656082View on ClinicalTrials.gov

Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 1, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Lupus Erythematosus, DiscoidLupus Erythematosus, CutaneousLupus Erythematosus, Chronic Cutaneous
Interventions
DRUG

Etanercept

Treatment with etanercept is intended for remission induction of DLE only and not for maintenance purpose.

Trial Locations (1)

LS7 4SA

Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds

Sponsors
All Listed Sponsors
collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

collaborator

Pfizer

INDUSTRY

collaborator

Clinical Trials Research Unit, Leeds

UNKNOWN

lead

University of Leeds

OTHER

NCT02656082 - Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus | Biotech Hunter | Biotech Hunter